Supplement
Benfotiamine
SaveA synthetic lipid-soluble thiamine derivative with substantially higher bioavailability than water-soluble B1, studied primarily in diabetic complications.
Quick verdict
Well-supported for diabetic neuropathy and AGE inhibition. The preferred B1 form when therapeutic tissue levels are desired.
Evidence score
A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.
What the research shows
Clinical trials demonstrate improved neuropathy scores in diabetic patients. Inhibits advanced glycation end-products (AGEs) formation in vitro and in vivo. Blood thiamine levels rise 5–10x higher than with thiamine HCl.
Benefits
- 5–10x higher blood thiamine levels vs standard B1
- Reduces AGE formation
- Improves diabetic neuropathy scores
Dosage notes
150–600 mg/day in divided doses. Diabetic neuropathy trials typically use 300–600 mg/day.
Side effects
- Mild GI upset
- Rare skin reactions
Who should be cautious
Not a substitute for blood glucose management in diabetics. Limited data in non-diabetic populations.
What this page cannot tell you
Most clinical evidence is in diabetic populations. Benefits in healthy individuals are theoretical.
Leaderboard scores
- Pain48
- Energy35
- Longevity30
Write a review
Sign in to write a review.